Pediatrics

Researchers at the University of Colorado Anschutz Medical Campus found that characters with crossed or drifting eyes are more likely to play more minor roles in animated movies and be considered unintelligent or villainous. These depictions, the researchers say, can have harmful effects for children with strabismus by perpetuating stereotypes.

In the wake of a report by a group of researchers in China detailing the increasing prevalence of myopia worldwide, Daniel Cyr, MD, a pediatric ophthalmologist at Stony Brook Medicine, agreed with its assessment, telling Ophthalmology Times he is seeing an increase in pediatric myopia at his clinic in New York.

Research is needed to establish the best diagnostic and management strategies for increasingly common condition

The designations underscore the unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists.

NEI Initiative aims to boost awareness, standardize diagnosis, and improve care for children with CVI through multidisciplinary collaboration and emerging technologies.

Analysis highlights discrepancies between adult, pediatric cataract procedures.

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

NEI Initiative aims to boost awareness, standardize diagnosis, and improve care for children with CVI through multidisciplinary collaboration and emerging technologies.

A study clarifies the relationship between postnatal weight gain and ROP development.

According to a presentation at the American Academy of Ophthalmology’s annual meeting in Chicago, a new study shows customized eyeglasses successfully addressed children’s complex eye needs.

A team of researchers at Arizona State University has developed tools to aid in the diagnosis of myopic maculopathy.

Coordinated by the International Agency for the Prevention of Blindness under the Love Your Eyes campaign banner, World Sight Day 2024 is putting children front and center in this year’s campaign.

Presented by the National Center for Children’s Vision and Eye Health at Prevent Blindness, the Bonnie Strickland Champion for Children’s Vision Award recognizes efforts by an individual or group of individuals, to improve public health approaches for children’s vision and eye health.

The report urges the US Department of Health and Human Services, in collaboration with departments of education at the state level, to take measures to ensure that children receive a vision screening before first grade and a comprehensive eye exam, when needed.

According to the organization, the map and report provide public, professionals and decisionmakers with data on children’s vision issues at the county and state level.

Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

CN6 palsy from the COVID-19 virus is rare, and can occur in infants as young as 7 months.

Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

Prevent Blindness provides opportunities for awareness and action in support of new legislation to provide much-needed funding for children’s vision programs in the United States.

The approach to treating amblyopia in young children couples proprietary therapeutic software with virtual reality (VR) headsets and popular children's TV shows

NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period.

The Type A meeting addressed questions the FDA had about the late-stage product candidate

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Data from the trial found that MyopiaX proved clinically safe and tolerable, in addition to showing clinical effect on the rate of myopia progression.